Afrezza® INHALE-1 Study in Pediatrics
Trial details
- Registry ID
- NCT04974528
- Drugs studied
- Afrezza, Basal Insulin, Rapid-acting Insulin Analog
TrialRedline tracks 3 clinical trials sponsored by Mannkind Corporation: 2 Phase 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Afrezza® INHALE-1 Study in PediatricsNCT04974528 | Afrezza, Basal Insulin, Rapid-acting Insulin Analog | Completed | 2024-10-03Actual |
| ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation SuspensionNCT06418711 | Clofazimine Inhalation Suspension | Terminated | 2025-11-10Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesNCT07224321 | Basal insulin, Technosphere Insulin | Recruiting | 2027-03Estimated |
Names as written in the registry records.
NCT07224321 · Mannkind Corporation
Before: Nov 2026. After: Mar 2027.
NCT07224321 · Mannkind Corporation
Before: Oct 2026. After: Nov 2026.
Before: Not yet recruiting. After: Recruiting.
NCT07224321 · Mannkind Corporation
Before: Sep 2026. After: Oct 2026.